Equity Overview
Price & Market Data
Price: $1.77
Daily Change: +$0.441 / 24.89%
Range: $1.42 - $1.96
Market Cap: $3,663,188
Volume: 3,712,535
Performance Metrics
1 Week: -2.25%
1 Month: -5.72%
3 Months: -68.12%
6 Months: -87.77%
1 Year: -92.22%
YTD: -84.98%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.